13 completed. 13 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 13 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Vaso-Occlusive Crises: new trials by email Literature Review of Vaso-Occlusive Crises trials Research Report on Vaso-Occlusive Crises
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease Etavopivat tablets - Sickle Cell Disease, Thalassemia | Phase 2 | Completed | Forma Therapeutics, Inc. | 53 | 2022-03-28 | 2025-12-16 |
| Interest of Famotidine in Children With Sickle Cell Disease Famotidine 400 mg/50 mL - Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2022-01-12 | 2025-10-08 |
| Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia Omega 3, Vit D, Zinc sulfate - Vaso-occlusive Crisis, Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Beni-Suef University | 350 | 2019-11-01 | 2021-01-27 |
| Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC) crizanlizumab - Sickle Cell Disease (SCD) | Phase 2 | Completed | Novartis Pharmaceuticals | 57 | 2017-12-19 | 2024-10-09 |
| A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients SANGUINATE 320 mg/kg, Normal Saline - Anemia, Sickle Cell | Phase 2 | Completed | Prolong Pharmaceuticals | 34 | 2016-07-01 | 2018-05-23 |
| Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis Ketamine - Sickle Cell Disease, Vaso-Occlusive Crisis | Phase 2 | Completed | UCSF Benioff Children's Hospital Oakland | 62 | 2016-06-01 | 2021-04-20 |
| Nitrous Oxide Analgesia Vaso-occlusive Crisis Nitrous oxide 50% - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 2 | Completed | Columbia University | 5 | 2013-11-12 | 2026-01-28 |
| Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease Proguanil, mefloquine plus artesunate, Sulfadoxine-pyrimethamine plus amodiaquine - Malaria, Sickle Cell Crisis | Phase 1 / Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 270 | 2011-09-01 | 2014-03-21 |
| Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo Placebo, Dalteparin - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 2 | Completed | Duke University | 34 | 2011-05-01 | 2015-02-16 |
| Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis GMI-1070, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 2 | Completed | GlycoMimetics Incorporated | 81 | 2010-05-01 | 2020-05-13 |
| IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome A-001, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 2 | Completed | Anthera Pharmaceuticals | 30 | 2006-12-01 | 2014-03-04 |
| Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises Nitric Oxide, Placebo - Anemia, Sickle Cell | Phase 2 | Completed | Mallinckrodt | 150 | 2004-10-01 | 2020-02-05 |
| Effectiveness of Arginine as a Treatment for Sickle Cell Anemia Arginine, Placebo - Anemia, Sickle Cell | Phase 2 | Completed | UCSF Benioff Children's Hospital Oakland | 128 | 2004-06-01 | 2017-03-29 |
Anemia, Sickle Cell (13) · Anemia (3) · Acute Chest Syndrome (1) · Anemia, Hemolytic (1) · Emergencies (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemoglobin SC Disease (1) · Hemoglobinopathies (1) · Hemolysis (1) · Malaria (1) · Sickle Cell Trait (1) · Thalassemia (1) · alpha-Thalassemia (1)
Anemia, Hemolytic, Congenital (13) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13) · Hemic and Lymphatic Diseases (13) · Anemia, Hemolytic (12) · Genetic Diseases, Inborn (12) · Hematologic Diseases (12) · Hemoglobinopathies (12) · Anemia (10) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Disease Attributes (1) · Infections (1) · Lung Diseases (1) · Mosquito-Borne Diseases (1) · Parasitic Diseases (1)
Amodiaquine (1) · Arginine (1) · Artesunate (1) · Cardiovascular Agents (1) · Dalteparin (1) · Docosahexaenoic Acids (1) · Endothelium-Dependent Relaxing Factors (1) · Famotidine (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Hydroxyurea (1) · Ketamine (1) · Mefloquine (1) · Morphine (1) · Nitric Oxide (1) · PEGylated carboxyhemoglobin bovine (1)
UCSF Benioff Children's Hospital Oakland (2) · Anthera Pharmaceuticals (1) · Assistance Publique - Hôpitaux de Paris (1) · Beni-Suef University (1) · Columbia University (1) · Duke University (1) · Forma Therapeutics, Inc. (1) · GlycoMimetics Incorporated (1) · London School of Hygiene and Tropical Medicine (1) · Mallinckrodt (1) · Novartis Pharmaceuticals (1) · Prolong Pharmaceuticals (1)
United States (9) · Canada (2) · Egypt (2) · Colombia (1) · Dominican Republic (1) · France (1) · Honduras (1) · Italy (1) · Lebanon (1) · Nigeria (1) · Panama (1) · Saudi Arabia (1) · United Kingdom (1)
Ahmed F Mahmoud Hussein, MS.c (1) · Carlton Dampier, MD (1) · Carolyn Bigelow, MD (1) · Cynthia Rutherford, MD (1) · Daniel S Tsze, MD, MPH (1) · Helen Thackray, MD (1) · Hemant Misra, PhD (1) · James Baldassarre, MD (1) · Joan Parkhurst Cain, MD (1) · Jonathan B Cooper-Sood, MD (1) · Kalifa Bojang, PhD (1) · Kathryn Hassell, MD (1)
PMID 21364138, PMID 22129980, PMID 25701866, PMID 25733584, PMID 35120836, PMID 36355805, PMID 36529836, PMID 37722599, PMID 38775255, PMID 39497751, PMID 41315052
U54HL070587 (1)